Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study
PsiquiatriaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of substance use and addiction treatment
- Publicado em
- 30 mar 2023
- Citações
- 10
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study
Laurent Elkrief, Gabriel Bastien, Christina McAnulty, Hamzah Bakouni, Francois-Olivier Hebert, M Eugenia Socias, Bernard Le Foll, Ron Lim, Omar Ledjiar, Stephanie Marsan et al.
Descritores MeSH
- Buprenorphine
- Opioid-Related Disorders
- Substance Withdrawal Syndrome
- Cannabis
- Methadone
- Narcotic Antagonists
- Buprenorphine, Naloxone Drug Combination
- Opiate Substitution Treatment
- Analgesics, Opioid
- Bayes Theorem
Veja também
Estudos relacionados
- Oral methadone versus sublingual buprenorphine for the treatment of acute opioid withdrawal: A triple-blind, double-dummy, randomized control trial
- Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study
- Opioid agonist treatment outcomes among individuals with a history of nonfatal overdose: Findings from a pragmatic, pan-Canadian, randomized control trial
- Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial